Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/104566
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts
Author: Theocharides, A.
Dobson, S.
Laurenti, E.
Notta, F.
Voisin, V.
Cheng, P.-Y.
Yuan, J.
Guidos, C.
Minden, M.
Mullighan, C.
Torlakovic, E.
Dick, J.
Citation: Leukemia, 2015; 29(1):177-187
Publisher: Nature Publishing Group
Issue Date: 2015
ISSN: 0887-6924
1476-5551
Statement of
Responsibility: 
A P A Theocharides, S M Dobson, E Laurenti, F Notta, V Voisin, P-Y Cheng, J S Yuan, C J Guidos, M D Minden, C G Mullighan, E Torlakovic and J E Dick
Abstract: Historically, our understanding of mechanisms underlying human leukemogenesis are inferred from genetically engineered mouse models. Relatively, few models that use primary human cells recapitulate the full leukemic transformation as assayed in xenografts and myeloid transformation is infrequent. We report a humanized experimental leukemia model where xenografts develop aggressive acute myeloid leukemia (AML) with disseminated myeloid sarcomas within 4 weeks following transplantation of cord blood transduced with vectors expressing BCR-ABL1 and a dominant-negative isoform of IKAROS, Ik6. Ik6 induced transcriptional programs in BCR-ABL1-transduced progenitors that contained repressed B-cell progenitor programs, along with strong stemness, proliferation and granulocyte-monocytic progenitor (GMP) signatures-a novel combination not induced in control groups. Thus, wild-type IKAROS restrains stemness properties and has tumor suppressor activity in BCR-ABL1-initiated leukemia. Although IKAROS mutations/deletions are common in lymphoid transformation, they are found also at low frequency in AML that progress from a prior myeloproliferative neoplasm (MPN) state. Our experimental system provides an excellent model to gain insight into these rare cases of AML transformation and the properties conferred by IKAROS loss of function as a secondary mutation. More generally, our data points to the importance of deregulated stemness/lineage commitment programs in human myeloid leukemogenesis.
Keywords: Leukemia, Myeloid, Acute
Rights: © 2015 Macmillan Publishers Limited. All rights reserve
DOI: 10.1038/leu.2014.150
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.